Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer

INTRODUCTION: We have shown previously that treatment with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) reduced the expression of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor type 2 (VEGFR2) and growth of 4T1-breast cancer (BC) in syngeneic mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Rene Gonzalez, Ruben, Watters, Amber, Xu, Yanbo, Singh, Udai P, Mann, David R, Rueda, Bo R, Penichet, Manuel L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716504/
https://www.ncbi.nlm.nih.gov/pubmed/19531256
http://dx.doi.org/10.1186/bcr2321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716504/
https://www.ncbi.nlm.nih.gov/pubmed/19531256
http://dx.doi.org/10.1186/bcr2321

Ejemplares similares